Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice

Dana M. Harris, Fernando F. Stancampiano, M. Caroline Burton, Ann M. Moyer, Michael J. Schuh, Jose R. Valery, Yan Bi

Research output: Contribution to journalReview articlepeer-review

Abstract

Prescribing the right medication, at the right dose, to the right patient is the goal of every physician. Pharmacogenomic information is an emerging tool that can be used to deliver precision medicine. In this review, we discuss the pharmacogenomics of available PPIs, racial differences of CYP2C19 and how PPI pharmacogenomics affects the treatment of common gastrointestinal diseases. We also provide practical guidance on when to order pharmacogenomic testing, which test to order, and how to modify treatment based on published guidelines.

Original languageEnglish (US)
Pages (from-to)4120-4127
Number of pages8
JournalDigestive diseases and sciences
Volume66
Issue number12
DOIs
StatePublished - Dec 2021

Keywords

  • Gastroesophageal reflux disease
  • Helicobacter pylori
  • Pharmacogenomics
  • Proton pump inhibitors

ASJC Scopus subject areas

  • Physiology
  • Gastroenterology

Fingerprint

Dive into the research topics of 'Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice'. Together they form a unique fingerprint.

Cite this